WALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on
the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing processes, today
announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2018 Global Healthcare Conference. The
conference will take place on June 5-8 in New York City, and the Repligen presentation is scheduled for Wednesday, June 6 at 3:00
p.m. EDT.
A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time
following the live event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products
that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein products
(Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns, chromatography
resins, ELISA kits) and Filtration products (including XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF cassettes, and Spectrum
KrosFlo™ hollow fiber TFF cartridges and systems). The Protein A ligands and growth factors that we produce are key components of
Protein A affinity resins and cell culture media, respectively. Protein A affinity resins are the industry standard for downstream
separation and purification of monoclonal antibody-based therapeutics. Growth factors are used in upstream processes to accelerate
cell growth and productivity. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench- through
commercial-scale purification needs, are delivered pre-packed to our customers with their choice of resin and to their bed height
preferences. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from
a bioreactor to concentrate cells and significantly increase productivity in upstream processes. Single-use SIUS™ TFF cassettes and
hardware are used for biologic drug concentration in downstream filtration processes, and Spectrum KrosFlo™ TFF cartridges and
systems are used in both upstream and downstream filtration processes. Repligen’s corporate headquarters are in Waltham, MA (USA),
with additional administrative and manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and Ravensburg,
Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which are not strictly historical statements including, without
limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to
time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Source:
Repligen Corporation
Sondra Newman
Senior Director Investor Relations
(781) 419-1881
snewman@repligen.com
